Systemic therapy of elderly patients with advanced non-small cell lung cancer—individualized treatment is key

Approximately 2.1 million individuals are diagnosed with lung cancer worldwide every year. Non-small cell lung cancer (NSCLC) comprises 80−85% of these cancers. About 40% of patients with NSCLC present with advanced disease at the time of initial diagnosis and receive palliative therapy. Patients without documented driver mutations in their cancers receive first-line chemotherapy with platinum-based doublets.